Sarcomatoid carcinoma of the lung
Prepared with OnCo (onco.cc/prep/pulmonary-sarcomatoid-carcinoma/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
8 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example MET exon 14 skipping, MET amplification and overexpression, KRAS, TP53, PIK3CA, STK11 and RB1 mutations, PD-L1, Cytokeratin positivity in the spindle component), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (all stages), which of the standard options do you recommend and why?
- 6.Am I a candidate for Capmatinib, Tepotinib, and what side effects should I expect?
- 7.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 8.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
Tests and results to bring
Biomarker results to ask for: MET exon 14 skipping (7.3 percent), MET amplification and overexpression, KRAS, TP53, PIK3CA, STK11 and RB1 mutations (Liu 2016), PD-L1, Cytokeratin positivity in the spindle component (distinguishes it from sarcoma).
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- All stages: Treated as non-small-cell lung cancer by stage; MET exon 14 skipping treated on the MET-altered page with capmatinib or tepotinib. (Non-small-cell lung cancer, MET exon 14 and MET-amplified non-small-cell lung cancer, Capmatinib, Tepotinib)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.